ID   Capan-2
AC   CVCL_0026
SY   CaPan-2; CAPAN-2; Capan 2; CAPAN 2; Capan2; CAPAN2
DR   BTO; BTO:0002745
DR   CLO; CLO_0002198
DR   EFO; EFO_0002154
DR   MCCL; MCC:0000127
DR   CLDB; cl642
DR   CLDB; cl643
DR   CLDB; cl644
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-80
DR   BCRJ; 0060
DR   BioSample; SAMN03472025
DR   BioSample; SAMN03473387
DR   BioSample; SAMN10988212
DR   cancercelllines; CVCL_0026
DR   Cell_Model_Passport; SIDM00943
DR   CGH-DB; 163-1
DR   CGH-DB; 9270-4
DR   ChEMBL-Cells; CHEMBL3308720
DR   ChEMBL-Targets; CHEMBL1075417
DR   CLS; 300144
DR   Cosmic; 730527
DR   Cosmic; 736271
DR   Cosmic; 755303
DR   Cosmic; 808163
DR   Cosmic; 868246
DR   Cosmic; 910915
DR   Cosmic; 913303
DR   Cosmic; 922256
DR   Cosmic; 923167
DR   Cosmic; 932517
DR   Cosmic; 932987
DR   Cosmic; 933522
DR   Cosmic; 934554
DR   Cosmic; 947396
DR   Cosmic; 948727
DR   Cosmic; 949232
DR   Cosmic; 1006366
DR   Cosmic; 1108339
DR   Cosmic; 1299297
DR   Cosmic; 1320463
DR   Cosmic; 1366277
DR   Cosmic; 1571775
DR   Cosmic; 1995363
DR   Cosmic; 2009527
DR   Cosmic; 2046535
DR   Cosmic; 2434087
DR   Cosmic; 2668288
DR   Cosmic-CLP; 910915
DR   DepMap; ACH-000107
DR   DSMZ; ACC-245
DR   DSMZCellDive; ACC-245
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 910915
DR   GEO; GSM206453
DR   GEO; GSM621896
DR   GEO; GSM784710
DR   GEO; GSM886921
DR   GEO; GSM887987
DR   GEO; GSM1024399
DR   GEO; GSM1374440
DR   GEO; GSM1669664
DR   IARC_TP53; 313
DR   IARC_TP53; 21042
DR   IARC_TP53; 30199
DR   IGRhCellID; Capan2
DR   IZSLER; BS TCL 10
DR   KCLB; 30080
DR   LiGeA; CCLE_178
DR   LINCS_LDP; LCL-1733
DR   Lonza; 1464
DR   MetaboLights; MTBLS812
DR   PharmacoDB; Capan2_185_2019
DR   PRIDE; PXD003198
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0026
DR   PubChem_Cell_line; CVCL_0026
DR   SKY/M-FISH/CGH; 1993
DR   Wikidata; Q54808591
RX   CelloPub=CLPUB00416;
RX   DOI=10.4172/jpb.1000057;
RX   PubMed=1630814;
RX   PubMed=1764370;
RX   PubMed=3019537;
RX   PubMed=3518877;
RX   PubMed=6582512;
RX   PubMed=6935474;
RX   PubMed=7459858;
RX   PubMed=7809022;
RX   PubMed=7961102;
RX   PubMed=7972006;
RX   PubMed=8026879;
RX   PubMed=8194712;
RX   PubMed=8286197;
RX   PubMed=8426738;
RX   PubMed=10027410;
RX   PubMed=11169957;
RX   PubMed=11169959;
RX   PubMed=11668190;
RX   PubMed=12692724;
RX   PubMed=12800145;
RX   PubMed=14695172;
RX   PubMed=15126341;
RX   PubMed=15367885;
RX   PubMed=15688027;
RX   PubMed=15770730;
RX   PubMed=18298655;
RX   PubMed=18380791;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20418756;
RX   PubMed=22460905;
RX   PubMed=22585861;
RX   PubMed=24700732;
RX   PubMed=25167228;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26216984;
RX   PubMed=26589293;
RX   PubMed=27259358;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31037374;
RX   PubMed=31068700;
RX   PubMed=35839778;
WW   https://www.cellosaurus.org/pawefish/PancCellLineDescriptions/capan-2.html
WW   http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=Capan-2
WW   https://www.proteinatlas.org/learn/cellines
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/c/cell-lines-detail-178.html
WW   https://www.mskcc.org/research-advantage/support/technology/tangible-material/capan-2-human-pancreatic-adenocarcinoma-cell-line
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: NCI RAS program mutant KRAS cell line panel.
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2000-049.
CC   Population: Caucasian.
CC   Doubling time: 96 hours (PubMed=3019537); 45-60 hours (CLS=300144); ~50-70 hours (DSMZ=ACC-245).
CC   HLA typing: A*29:02,29:02; B*44:03,44:03; C*16:01,16:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Thr18_Ala19dup (c.52_57dupACGGCC); ClinVar=VCV000579466; Zygosity=Homozygous (PubMed=7972006; DepMap).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=7961102; PubMed=8026879; PubMed=8426738; PubMed=11169959; PubMed=15367885; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Thr (c.375G>T); ClinVar=VCV000237948; Zygosity=Homozygous; Note=Impairs TP53 splicing dramatically (PubMed=7961102; PubMed=8026879; PubMed=24700732; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Deep antibody staining analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Metabolome analysis.
CC   Omics: Proteome analysis by 2D-DE/MS.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.28%; Native American=0.63%; East Asian, North=0.28%; East Asian, South=0%; South Asian=0.34%; European, North=62.52%; European, South=35.95% (PubMed=30894373).
CC   Caution: TP53 mutation indicated incorrectly as being at c.818G>A in PubMed=1630814.
CC   Misspelling: CANPAN-2; Cosmic=2434087.
CC   Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.
ST   Source(s): ATCC; CLS; Cosmic-CLP; DSMZ; KCLB; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,12
ST   D16S539: 9,13
ST   D18S51: 13
ST   D19S433: 13,15
ST   D21S11: 31
ST   D2S1338: 19,25
ST   D3S1358: 17,18
ST   D5S818: 11,12
ST   D7S820: 9,11
ST   D8S1179: 12,13
ST   FGA: 21,24
ST   Penta D: 13,15
ST   Penta E: 11
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 16,17 (DSMZ)
ST   vWA: 17 (ATCC; CLS; Cosmic-CLP; PubMed=25877200)
ST   vWA: 17,19 (KCLB)
DI   NCIt; C9120; Pancreatic ductal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 44
//
RX   CelloPub=CLPUB00416;
RA   Oberlin L.;
RT   "Treatment of pancreatic carcinoma cell lines in vitro and vivo with a
RT   monoclonal antibody against the transferrin receptor.";
RL   Thesis VMD (2009), Justus-Liebig-Universitat Giessen, Germany.
//
RX   DOI=10.4172/jpb.1000057;
RA   Yamada M., Fujii K., Koyama K., Hirohashi S., Kondo T.;
RT   "The proteomic profile of pancreatic cancer cell lines corresponding
RT   to carcinogenesis and metastasis.";
RL   J. Proteomics Bioinformatics 2:1-18(2009).
//
RX   PubMed=1630814;
RA   Ruggeri B., Zhang S.-Y., Caamano J., DiRado M., Flynn S.D.,
RA   Klein-Szanto A.J.P.;
RT   "Human pancreatic carcinomas and cell lines reveal frequent and
RT   multiple alterations in the p53 and Rb-1 tumor-suppressor genes.";
RL   Oncogene 7:1503-1511(1992).
//
RX   PubMed=1764370; DOI=10.1038/bjc.1991.467;
RA   Barton C.M., Staddon S.L., Hughes C.M., Hall P.A., O'Sullivan C.,
RA   Kloppel G., Theis B., Russell R.C.G., Neoptolemos J., Williamson R.C.N.,
RA   Lane D.P., Lemoine N.R.;
RT   "Abnormalities of the p53 tumour suppressor gene in human pancreatic
RT   cancer.";
RL   Br. J. Cancer 64:1076-1082(1991).
//
RX   PubMed=3019537;
RA   Kyriazis A.A., Kyriazis A.P., Sternberg C.N., Sloane N.H.,
RA   Loveless J.D.;
RT   "Morphological, biological, biochemical, and karyotypic
RT   characteristics of human pancreatic ductal adenocarcinoma Capan-2 in
RT   tissue culture and the nude mouse.";
RL   Cancer Res. 46:5810-5815(1986).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=6935474; DOI=10.1093/jnci/66.2.239;
RA   Wright W.C., Daniels W.P., Fogh J.;
RT   "Distinction of seventy-one cultured human tumor cell lines by
RT   polymorphic enzyme analysis.";
RL   J. Natl. Cancer Inst. 66:239-247(1981).
//
RX   PubMed=7459858;
RA   Rousset M., Zweibaum A., Fogh J.;
RT   "Presence of glycogen and growth-related variations in 58 cultured
RT   human tumor cell lines of various tissue origins.";
RL   Cancer Res. 41:1165-1170(1981).
//
RX   PubMed=7809022; DOI=10.1097/00006676-199409000-00018;
RA   Sumi S., Beauchamp R.D., Townsend C.M. Jr., Pour P.M., Ishizuka J.,
RA   Thompson J.C.;
RT   "Lovastatin inhibits pancreatic cancer growth regardless of RAS
RT   mutation.";
RL   Pancreas 9:657-661(1994).
//
RX   PubMed=7961102; DOI=10.1111/j.1349-7006.1994.tb02898.x;
RA   Suwa H., Yoshimura T., Yamaguchi N., Kanehira K., Manabe T.,
RA   Imamura M., Hiai H., Fukumoto M.;
RT   "K-ras and p53 alterations in genomic DNA and transcripts of human
RT   pancreatic adenocarcinoma cell lines.";
RL   Jpn. J. Cancer Res. 85:1005-1014(1994).
//
RX   PubMed=7972006; DOI=10.1073/pnas.91.23.11045;
RA   Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P.,
RA   Bennett W.P., Forrester K., Gerwin B.I., Serrano M., Beach D.H.,
RA   Harris C.C.;
RT   "Mutations and altered expression of p16INK4 in human cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994).
//
RX   PubMed=8026879; DOI=10.1002/ijc.2910580207;
RA   Berrozpe G., Schaeffer J., Peinado M.A., Real F.X., Perucho M.;
RT   "Comparative analysis of mutations in the p53 and K-ras genes in
RT   pancreatic cancer.";
RL   Int. J. Cancer 58:185-191(1994).
//
RX   PubMed=8194712; DOI=10.1016/0016-5085(94)90422-7;
RA   Simon B., Weinel R., Hohne M., Watz J., Schmidt J., Kortner G.,
RA   Arnold R.;
RT   "Frequent alterations of the tumor suppressor genes p53 and DCC in
RT   human pancreatic carcinoma.";
RL   Gastroenterology 106:1645-1651(1994).
//
RX   PubMed=8286197; DOI=10.1038/bjc.1994.24;
RA   Lohr J.-M., Trautmann B., Gottler M., Peters S., Zauner I., Maillet B.,
RA   Kloppel G.;
RT   "Human ductal adenocarcinomas of the pancreas express extracellular
RT   matrix proteins.";
RL   Br. J. Cancer 69:144-151(1994).
//
RX   PubMed=8426738;
RA   Kalthoff H., Schmiegel W.H., Roeder C., Kasche D., Schmidt A., Lauer G.,
RA   Thiele H.-G., Honold G., Pantel K., Riethmuller G., Scherer E.,
RA   Maurer J., Maacke H., Deppert W.;
RT   "p53 and K-RAS alterations in pancreatic epithelial cell lesions.";
RL   Oncogene 8:289-298(1993).
//
RX   PubMed=10027410; DOI=10.1016/S0002-9440(10)65298-4;
RA   Ghadimi B.M., Schrock E., Walker R.L., Wangsa D., Jauho A.,
RA   Meltzer P.S., Ried T.;
RT   "Specific chromosomal aberrations and amplification of the AIB1
RT   nuclear receptor coactivator gene in pancreatic carcinomas.";
RL   Am. J. Pathol. 154:525-536(1999).
//
RX   PubMed=11169957; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1014>3.0.CO;2-U;
RA   Wallrapp C., Hahnel S., Boeck W., Soder A., Mincheva A., Lichter P.,
RA   Leder G., Gansauge F., Sorio C., Scarpa A., Gress T.M.;
RT   "Loss of the Y chromosome is a frequent chromosomal imbalance in
RT   pancreatic cancer and allows differentiation to chronic
RT   pancreatitis.";
RL   Int. J. Cancer 91:340-344(2001).
//
RX   PubMed=11169959; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.0.CO;2-C;
RA   Sirivatanauksorn V., Sirivatanauksorn Y., Gorman P.A., Davidson J.M.,
RA   Sheer D., Moore P.S., Scarpa A., Edwards P.A.W., Lemoine N.R.;
RT   "Non-random chromosomal rearrangements in pancreatic cancer cell lines
RT   identified by spectral karyotyping.";
RL   Int. J. Cancer 91:350-358(2001).
//
RX   PubMed=11668190; DOI=10.1177/002215540104901105;
RA   Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.;
RT   "Immunocytochemical analysis of cell lines derived from solid
RT   tumors.";
RL   J. Histochem. Cytochem. 49:1369-1378(2001).
//
RX   PubMed=12692724; DOI=10.1007/s00428-003-0784-4;
RA   Sipos B., Moser S., Kalthoff H., Torok V., Lohr J.-M., Kloppel G.;
RT   "A comprehensive characterization of pancreatic ductal carcinoma cell
RT   lines: towards the establishment of an in vitro research platform.";
RL   Virchows Arch. 442:444-452(2003).
//
RX   PubMed=12800145; DOI=10.1002/gcc.10218;
RA   Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B.,
RA   Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A.,
RA   Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D.,
RA   Edwards P.A.W., Chaffanet M.;
RT   "A recurrent chromosome translocation breakpoint in breast and
RT   pancreatic cancer cell lines targets the neuregulin/NRG1 gene.";
RL   Genes Chromosomes Cancer 37:333-345(2003).
//
RX   PubMed=14695172;
RA   Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., Adsay N.V.,
RA   Shen-Ong G.L., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J.,
RA   Kern S.E., Goggins M.G., Hruban R.H.;
RT   "Highly expressed genes in pancreatic ductal adenocarcinomas: a
RT   comprehensive characterization and comparison of the transcription
RT   profiles obtained from three major technologies.";
RL   Cancer Res. 63:8614-8622(2003).
//
RX   PubMed=15126341; DOI=10.1158/0008-5472.CAN-03-3159;
RA   Heidenblad M., Schoenmakers E.F.P.M., Jonson T., Gorunova L.,
RA   Veltman J.A., van Kessel A.G., Hoglund M.;
RT   "Genome-wide array-based comparative genomic hybridization reveals
RT   multiple amplification targets and novel homozygous deletions in
RT   pancreatic carcinoma cell lines.";
RL   Cancer Res. 64:3052-3059(2004).
//
RX   PubMed=15367885; DOI=10.1097/00006676-200410000-00004;
RA   Loukopoulos P., Kanetaka K., Takamura M., Shibata T., Sakamoto M.,
RA   Hirohashi S.;
RT   "Orthotopic transplantation models of pancreatic adenocarcinoma
RT   derived from cell lines and primary tumors and displaying varying
RT   metastatic activity.";
RL   Pancreas 29:193-203(2004).
//
RX   PubMed=15688027; DOI=10.1038/sj.onc.1208383;
RA   Heidenblad M., Lindgren D., Veltman J.A., Jonson T., Mahlamaki E.H.,
RA   Gorunova L., van Kessel A.G., Schoenmakers E.F.P.M., Hoglund M.;
RT   "Microarray analyses reveal strong influence of DNA copy number
RT   alterations on the transcriptional patterns in pancreatic cancer:
RT   implications for the interpretation of genomic amplifications.";
RL   Oncogene 24:1794-1801(2005).
//
RX   PubMed=15770730; DOI=10.3748/wjg.v11.i10.1521;
RA   Ma J.-H., Patrut E., Schmidt J., Knaebel H.-P., Buchler M.W.,
RA   Marten A.;
RT   "Synergistic effects of interferon-alpha in combination with
RT   chemoradiation on human pancreatic adenocarcinoma.";
RL   World J. Gastroenterol. 11:1521-1528(2005).
//
RX   PubMed=18298655; DOI=10.1111/j.1582-4934.2008.00289.x;
RA   Pilarsky C., Ammerpohl O., Sipos B., Dahl E., Hartmann A.,
RA   Wellmann A., Braunschweig T., Lohr J.-M., Jesenofsky R., Friess H.,
RA   Wente M.N., Kristiansen G., Jahnke B., Denz A., Ruckert F.,
RA   Schackert H.K., Kloppel G., Kalthoff H., Saeger H.-D., Grutzmann R.;
RT   "Activation of Wnt signalling in stroma from pancreatic cancer
RT   identified by gene expression profiling.";
RL   J. Cell. Mol. Med. 12:2823-2835(2008).
//
RX   PubMed=18380791; DOI=10.1111/j.1349-7006.2008.00779.x;
RA   Suzuki A., Shibata T., Shimada Y., Murakami Y., Horii A.,
RA   Shiratori K., Hirohashi S., Inazawa J., Imoto I.;
RT   "Identification of SMURF1 as a possible target for 7q21.3-22.1
RT   amplification detected in a pancreatic cancer cell line by in-house
RT   array-based comparative genomic hybridization.";
RL   Cancer Sci. 99:986-994(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20418756; DOI=10.1097/MPA.0b013e3181c15963;
RA   Deer E.L., Gonzalez-Hernandez J., Coursen J.D., Shea J.E., Ngatia J.,
RA   Scaife C.L., Firpo M.A., Mulvihill S.J.;
RT   "Phenotype and genotype of pancreatic cancer cell lines.";
RL   Pancreas 39:425-435(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224;
RA   Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K.,
RA   Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y.,
RA   van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J.,
RA   Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P.,
RA   Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L.,
RA   Rottapel R., Neel B.G., Moffat J.;
RT   "Essential gene profiles in breast, pancreatic, and ovarian cancer
RT   cells.";
RL   Cancer Discov. 2:172-189(2012).
//
RX   PubMed=24700732; DOI=10.1002/humu.22556;
RA   Leroy B., Girard L., Hollestelle A., Minna J.D., Gazdar A.F.,
RA   Soussi T.;
RT   "Analysis of TP53 mutation status in human cancer cell lines: a
RT   reassessment.";
RL   Hum. Mutat. 35:756-765(2014).
//
RX   PubMed=25167228; DOI=10.1038/bjc.2014.475;
RA   Hamidi H., Lu M., Chau K., Anderson L., Fejzo M.S., Ginther C.,
RA   Linnartz R., Zubel A., Slamon D.J., Finn R.S.;
RT   "KRAS mutational subtype and copy number predict in vitro response of
RT   human pancreatic cancer cell lines to MEK inhibition.";
RL   Br. J. Cancer 111:1788-1801(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26216984; DOI=10.1073/pnas.1501605112;
RA   Daemen A., Peterson D., Sahu N., McCord R., Du X.-N., Liu B.,
RA   Kowanetz K., Hong R., Moffat J., Gao M., Boudreau A., Mroue R.,
RA   Corson L., O'Brien T., Qing J., Sampath D., Merchant M., Yauch R.L.,
RA   Manning G., Settleman J., Hatzivassiliou G., Evangelista M.;
RT   "Metabolite profiling stratifies pancreatic ductal adenocarcinomas
RT   into subtypes with distinct sensitivities to metabolic inhibitors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27259358; DOI=10.1074/mcp.M116.058313;
RA   Humphrey E.S., Su S.-P., Nagrial A.M., Hochgrafe F., Pajic M.,
RA   Lehrbach G.M., Parton R.G., Yap A.S., Horvath L.G., Chang D.K.,
RA   Biankin A.V., Wu J.-M., Daly R.J.;
RT   "Resolution of novel pancreatic ductal adenocarcinoma subtypes by
RT   global phosphotyrosine profiling.";
RL   Mol. Cell. Proteomics 15:2671-2685(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31037374; DOI=10.1007/s00216-019-01814-1;
RA   Lagies S., Schlimpert M., Braun L.M., Kather M., Plagge J., Erbes T.,
RA   Wittel U.A., Kammerer B.;
RT   "Unraveling altered RNA metabolism in pancreatic cancer cells by
RT   liquid-chromatography coupling to ion mobility mass spectrometry.";
RL   Anal. Bioanal. Chem. 411:6319-6328(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//